Assembly Biosciences Inc (NASDAQ:ASMB) was the target of a significant drop in short interest in September. As of September 30th, there was short interest totalling 380,900 shares, a drop of 20.1% from the August 30th total of 476,500 shares. Based on an average daily trading volume, of 273,100 shares, the days-to-cover ratio is presently 1.4 days. Currently, 1.7% of the shares of the company are sold short.
A number of equities research analysts recently weighed in on the company. ValuEngine raised Assembly Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. BidaskClub cut shares of Assembly Biosciences from a “hold” rating to a “sell” rating in a research note on Monday, September 30th. Zacks Investment Research upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating and set a $13.00 price target for the company in a research note on Friday, September 27th. Chardan Capital restated a “neutral” rating on shares of Assembly Biosciences in a research note on Thursday, September 19th. Finally, William Blair restated a “buy” rating on shares of Assembly Biosciences in a research note on Wednesday, October 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $29.33.
ASMB traded up $0.30 during midday trading on Monday, reaching $9.01. 152,103 shares of the company’s stock were exchanged, compared to its average volume of 344,390. The firm has a market capitalization of $217.78 million, a price-to-earnings ratio of -2.26 and a beta of 1.46. The company has a quick ratio of 9.20, a current ratio of 9.20 and a debt-to-equity ratio of 0.06. Assembly Biosciences has a one year low of $8.13 and a one year high of $27.60. The business has a 50-day simple moving average of $11.23 and a two-hundred day simple moving average of $14.12.
Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.72) EPS for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.41. The firm had revenue of $3.08 million during the quarter, compared to analysts’ expectations of $3.90 million. Assembly Biosciences had a negative net margin of 622.25% and a negative return on equity of 46.33%. As a group, research analysts anticipate that Assembly Biosciences will post -3.64 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Jennison Associates LLC lifted its stake in Assembly Biosciences by 3.3% during the second quarter. Jennison Associates LLC now owns 2,555,637 shares of the biopharmaceutical company’s stock worth $34,476,000 after purchasing an additional 82,558 shares during the period. BlackRock Inc. raised its stake in shares of Assembly Biosciences by 1.9% in the second quarter. BlackRock Inc. now owns 1,773,321 shares of the biopharmaceutical company’s stock valued at $23,921,000 after acquiring an additional 33,328 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Assembly Biosciences by 13.6% in the second quarter. Vanguard Group Inc. now owns 1,226,953 shares of the biopharmaceutical company’s stock valued at $16,552,000 after acquiring an additional 146,452 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of Assembly Biosciences by 0.4% in the second quarter. Janus Henderson Group PLC now owns 956,634 shares of the biopharmaceutical company’s stock valued at $12,905,000 after acquiring an additional 3,749 shares during the last quarter. Finally, Rock Springs Capital Management LP raised its stake in shares of Assembly Biosciences by 24.4% in the second quarter. Rock Springs Capital Management LP now owns 560,000 shares of the biopharmaceutical company’s stock valued at $7,554,000 after acquiring an additional 110,000 shares during the last quarter. Hedge funds and other institutional investors own 82.00% of the company’s stock.
About Assembly Biosciences
Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.
Further Reading: What is Depreciation?
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.